


bsm-60900R**[Primary Antibody]****Bioss**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

CD19 Recombinant Rabbit mAb**— DATASHEET —****Host:** Rabbit**Isotype:** IgG**Clonality:** Recombinant**CloneNo.:** 7A6**GeneID:** 930**SWISS:** P15391**Target:** CD19**Immunogen:** A synthesized peptide derived from human CD19: 300-556.**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml**Storage:** 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.**Background:** This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]**Applications:** WB (1:500-2000)**IHC-P** (1:50-200)**IHC-F** (1:50-200)**IF** (1:50-200)**Flow-Cyt** (1:50-100)**ICC/IF** (1:50-200)**Reactivity:** Human**Predicted**
MW.: 59 kDa**Subcellular**
Location: Cell membrane**— VALIDATION IMAGES —**


25 ug total protein per lane of various lysates (see on figure) probed with CD19 monoclonal antibody, unconjugated (bsm-60900R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.




Paraformaldehyde-fixed, paraffin embedded Human Colon Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD19 Monoclonal Antibody, Unconjugated(bsm-60900R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Human Tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with CD19 Monoclonal Antibody, Unconjugated(bsm-60900R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



4% Paraformaldehyde-fixed Raji (H) cell;
Antibody incubation with (CD19) monoclonal
Antibody, unconjugated (bsm-60900R) 1:100, 90
min at 37°C; followed by conjugated Goat Anti-
Rabbit IgG antibody (green, bs-60295G-BF488) at
37°C for 90 min, DAPI (blue, C02-04002) was used
to stain the cell nuclei. PBS instead of the
primary antibody was used as the blank control.



The Raji (H) cells were incubated in 5%BSA to
block non-specific protein-protein interactions
(30 min at r.t.) , followed by secondary antibody
incubation for 40 min at room temperature.
Primary Antibody (green): Rabbit Anti-CD19
antibody (bsm-60900R,1:100); Isotype Control
(orange): Rabbit IgG (bs-0295P). Blank control
(black): PBS. Acquisition of 20,000 events was
performed.